Advertisement

Clinical Pharmacokinetics

, Volume 21, Issue 4, pp 274–284 | Cite as

Interleukins

Clinical Pharmacokinetics and Practical Implications
  • Velio Bocci
Review Articles Drug Disposition

Summary

Interleukins and tumour necrosis factor (TNF) are a complex group of proteins and glycoproteins able to exert pleiotropic effects with respect to a number of different target cells. In physiological conditions, they are induced and released in basal amounts only in restricted micro-environments where they have paracrine activity. Any small amounts reaching the circulation do not disturb homoeostasis. During therapy, particularly when these cytokines are administered via conventional routes, it has become apparent that their presence in nonphysiological plasma concentrations and their unselective action cause toxic effects with small benefits.

The pharmacokinetics of interleukins-1, -2, -3 and -6 and TNF have been evaluated, and their disappearance from plasma after intravenous administration is very rapid (i.e. the distribution half-life is measured in minutes; the elimination half-life is several hours). The efficiency of catabolic pathways such as renal filtration and/or liver uptake is interpreted as a salutary mechanism for extracting proteins that should not be in the circulation. However, because these cytokines are very potent immunomodulatory agents there is a need to improve their therapeutic index, and to this end a number of possible formulations and routes of administration are now available and may eventually be of practical use.

Keywords

Interferon Biological Response Modifier Capillary Leak Syndrome Recombinant Human Tumor Necrosis Factor Yale Journal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asher A, Mulé JJ, Reichert C, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systematically administered recombinant tumor necrosis factor against several murine tumors in vivo. Journal of Immunology 138: 963–974, 1987Google Scholar
  2. Ashwell G, Harford J. Carbohydrate — specific receptors of the liver. Annual Review of Biochemistry 51: 531–554, 1982PubMedCrossRefGoogle Scholar
  3. Baricos WH, Zhou Y, Fuerst RS, Barrett AJ, Shah SV. The role of aspartic and cysteine proteinases in albumin degradation by rat kidney cortical lysosomes. Archives of Biochemistry and Biophysics 256: 687–691, 1987PubMedCrossRefGoogle Scholar
  4. Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines: friends or foes. Immunology Today 11: 167–169, 1990PubMedCrossRefGoogle Scholar
  5. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. Journal of Immunology 135: 3972–3977, 1985Google Scholar
  6. Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, et al. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. British Journal of Cancer 47: 123–133, 1983PubMedCrossRefGoogle Scholar
  7. Blatteis CM. Neuromodulative actions of cytokines. Yale Journal of Biology and Medicine 63: 133–146, 1990PubMedGoogle Scholar
  8. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Research 47: 2986–2989, 1987PubMedGoogle Scholar
  9. Bocci V. Distribution of interferon in body fluids and tissues. Texas Reports on Biology and Medicine 35: 436–442, 1977PubMedGoogle Scholar
  10. Bocci V. What is the role of carbohydrates in interferons? Trends in Biochemical Sciences 8: 432–434, 1983CrossRefGoogle Scholar
  11. Bocci V. Evaluation of routes of administration of interferon in cancer: a review and a proposal. Cancer Drug Delivery 1: 337–351, 1984PubMedCrossRefGoogle Scholar
  12. Bocci V. Administration of interferon at night may increase its therapeutic index. Cancer drug Delivery 2: 313–318, 1985aPubMedCrossRefGoogle Scholar
  13. Bocci V. Immunomodulators as local hormones: new insights regarding their clinical utilization. Journal of Biological Response Modifiers 4: 340–352, 1985bPubMedGoogle Scholar
  14. Bocci V. Distribution, catabolism and pharmacokinetics of interferons. In Finter & Oldham (Eds) Interferon: in vivo and clinical studies, Vol. 4, pp. 47–72, Elsevier Science Publishers BV, Amsterdam, 1985cGoogle Scholar
  15. Bocci V. Metabolism of protein anticancer agents. Pharmacology and Therapeutics 34: 1–49, 1987PubMedCrossRefGoogle Scholar
  16. Bocci V. Roles of interferon produced in physiological conditions: a speculative review. Immunology 64: 1–9, 1988aPubMedGoogle Scholar
  17. Bocci V. Central nervous system toxicity of interferons and other cytokines. Journal of Biological Regulators and Homeostatic Agents 3: 107–118, 1988bGoogle Scholar
  18. Bocci V. Catabolism of therapeutic proteins and peptides with implications for drug delivery. Advanced Drug Delivery Reviews 4: 149–169, 1990aCrossRefGoogle Scholar
  19. Bocci V. Is interferon effective after oral administration? The state of the art. Journal of Biological Regulators and Homeostatic Agents 4: 81–83, 1990bPubMedGoogle Scholar
  20. Bocci V. What roles have anti-interferon antibodies in physiology and pathology? Research in Clinic and Laboratory, in press, 1991aGoogle Scholar
  21. Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP. Renal metabolism of rabbit serum interferon. Journal of General Virology 55: 297–304, 1981PubMedCrossRefGoogle Scholar
  22. Bocci V, Pacini a, Muscettola M, Pessina GP, Paulesu L, et al. The kidney is the main site of interferon catabolism. Journal of Interferon Research 2: 309–314, 1982PubMedCrossRefGoogle Scholar
  23. Bocci V, Pacini A, Pessina GP, Maioli E, Naldini A. Studies on tumor necrosis factor (TNF)-1. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administration. General Pharmacology 18: 343–346, 1987aPubMedCrossRefGoogle Scholar
  24. Bocci V, Pacini A, Pessina GP, Paulesu L, Muscettola M, et al. Catabolic sites of human interferon-γ. Journal of General Virology 66: 887–891, 1985aPubMedCrossRefGoogle Scholar
  25. Bocci V, Pessina GP, Pacini A, Paulesu L, Muscettola M, et al. Pulmonary catabolism of interferons: alveolar absorption of 125l-labeled human interferon alpha is accompanied by partial loss of biological activity. Antiviral Research 4: 211–220, 1984PubMedCrossRefGoogle Scholar
  26. Bocci V, Pessina GP, Pacini A, Paulesu L, Muscettola M, et al. Pharmacokinetics of human lymphoblastoid interferon in rabbits. General Pharmacology 16: 277–279, 1985bPubMedCrossRefGoogle Scholar
  27. Bocci V, Satoh Y, Pacini A, Pessina GP, Paulesu L, et al. Metabolic behaviour of recombinant interferons β. IRCS Medical Science Research 15: 187–188, 1987bGoogle Scholar
  28. Borth W, Luger TA. Identification of β2-microglobulin as a cytokine binding plasma protein. Journal of Biological Chemistry 264: 5818–5825, 1989PubMedGoogle Scholar
  29. Castell JV, Andus T, Kunz D, Heinrich PC. The major regulator of acute-phase protein synthesis in man and rat. In Sehgal et al. (Eds) Annals of the New York Academy of Sciences: regulation of the acute phase and immune responses — interlukin-6, Vol. 557, pp. 87–99, New York Academy of Sciences, New York, 1989Google Scholar
  30. Castell JV, Geiger T, Gross V, Andus T, Walter E, et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. European Journal of Biochemistry 177: 357–361, 1988PubMedCrossRefGoogle Scholar
  31. Chang AE, Hyatt CL, Rosenberg SA. Systemic administration of recombinant human interleukin-2 in mice. Journal of Biological Response Modifiers 3: 561–572, 1984PubMedGoogle Scholar
  32. Cheever MA, Thompson JA, Kern DE, Greenberg PD. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. Journal of Immunology 134: 3895–3900, 1985Google Scholar
  33. Conradt HS, Geyer R, Hoppe J, Grotjahn L, Plessing A, et al. Structures of the major carbohydrates of natural human interleukin-2. European Journal of Biochemistry 153: 255–261, 1985PubMedCrossRefGoogle Scholar
  34. Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemotherapy and Pharmacology 20: 137–144, 1987PubMedGoogle Scholar
  35. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. Journal of Immunology 130: 2203–2208, 1983Google Scholar
  36. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. Journal of Biological Chemistry 264: 11974–11980, 1989PubMedGoogle Scholar
  37. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. Journal of Clinical Oncology 6: 1328–1334, 1988PubMedGoogle Scholar
  38. Ferraiolo BL, Moore JA, Crase D, Gribling P, Wilking H, et al. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-α in mice. Drug Metabolism and Disposition 16: 270–275, 1988PubMedGoogle Scholar
  39. Ferraiolo BL, McCabe J, Hollenbach S, Hultgren B, Pitti R, et al. Pharmacokinetics of recombinant human tumor necrosis factor-α in rats: effects of size and number of doses and nephrectomy. Drug Metabolism and Disposition 17: 369–372, 1989PubMedGoogle Scholar
  40. Flick DA, Gifford GE. Pharmacokinetics of murine tumor necrosis factor. Journal of Immunopharmacology 8: 89–97, 1986PubMedCrossRefGoogle Scholar
  41. Fountoulakis M, Juranville JF, Stüber D, Weibel EK, Garotta G. Purification and biochemical characterization of a soluble human interferon γ receptor expressed in Escherichia coli. Journal of Biological Chemistry 265: 13268–13275, 1990PubMedGoogle Scholar
  42. Garland JM, Aldridge A, Wagstaffe J, Dexter TM. Studies on the in vivo production of a lymphokine activity, interleukin 3 (IL-3) elaborated by lymphocytes and a myeloid leukaemic line in vitro and the fate of IL-3 dependent cell lines. British Journal of Cancer 48: 247–259, 1983PubMedCrossRefGoogle Scholar
  43. Gaynor ER, Vitek L, Sticklin L, Creekmore SP, Ferraro ME, et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine 109: 953–958, 1988PubMedGoogle Scholar
  44. Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. New England Journal of Medicine 293: 702–705, 1975PubMedCrossRefGoogle Scholar
  45. Gresser I, Woodrow D, Moss J, Maury C, Tavernier J, et al. Toxic effects of recombinant tumor necrosis factor in suckling mice. American Journal of Pathology 128: 13–18, 1987PubMedGoogle Scholar
  46. Hirano T, Kishimoto T. Interleukin-6: possible implications in human diseases. Research in Clinic and Laboratory 19: 1–10, 1989PubMedGoogle Scholar
  47. James K. Interactions between cytokines and α2-macroglobulin. Immunology Today 11: 163–166, 1990PubMedCrossRefGoogle Scholar
  48. Jiang PH, Chany-Fournier F, Robert-Galliot B, Sarragne M, Chany C. Sarcolectin: an interferon antagonist extracted from hamster sarcomas and normal muscles. Journal of Biological Chemistry 258: 12361–12367, 1983PubMedGoogle Scholar
  49. Jones EY, Stuart DI, Walker NPC. Structure of tumour necrosis factor. Nature 338: 225–228, 1989PubMedCrossRefGoogle Scholar
  50. Kampschmidt RF, Jones T. Rate of clearance of interleukin-1 from the blood of normal and nephrectomized rats. Proceedings of the Society for Experimental Biology and Medicine 180: 170–173, 1985PubMedGoogle Scholar
  51. Kampschmidt RF, Upchurch HF. Rate of clearance of circulating leukocytic endogenous mediator in the rat. Proceedings of the Society for Experimental Biology and Medicine 164: 537–539, 1980PubMedGoogle Scholar
  52. Katre NV. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. Journal of Immunology 144: 209–213, 1990Google Scholar
  53. Kimball ES, Pickerai SF, Oppenheim JJ, Rossio JL. Interleukin 1 activitiy in normal human urine. Journal of Immunologyu 133: 256–260, 1984Google Scholar
  54. Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemotherapy and Pharmacology 20: 223–229, 1987PubMedCrossRefGoogle Scholar
  55. Klapproth J, Castell J, Geiger T, Andus T, Heinrich PC. Fate and biological action of human recombinant interleukin 1β in the rat in vivo. European Journal of Immunology 19: 1485–1490, 1989PubMedCrossRefGoogle Scholar
  56. Klausner JM, Goldman G, Skornick Y, Valeri R, Inbar M, et al. Interleukin-2-induced lung permeability is mediated by leukotriene B4. Cancer 66: 2357–2364, 1990PubMedCrossRefGoogle Scholar
  57. Knauf MJ, Bell DP, Hirtzer P, Ping Luo Z, Young JD, et al. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. Journal of Biological Chemistry 263: 15064–15070, 1988PubMedGoogle Scholar
  58. Konrad MW, Hemstreet G, Hersh EM, Mansell PWA, Mertelsmann R, et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Research 50: 2009–2017, 1990PubMedGoogle Scholar
  59. Krueger JM, Obal F, Opp M, Toth L, Johannsen L, et al. Somnogenic cytokines and models concerning their effects on sleep. Yale Journal of Biology and Medicine 63: 157–172, 1990PubMedGoogle Scholar
  60. Kucharz EJ, Goodwin JS. Serum inhibitors of interleukin-2. Life Sciences 42: 1485–1491, 1988PubMedCrossRefGoogle Scholar
  61. Kudo S, Mizuno K, Hirai Y, Shimizu T. Clearance and tissue distribution of recombinant human interleukin 1β in rats. Cancer Research 50: 5751–5755, 1990PubMedGoogle Scholar
  62. Langer R. New methods of drug delivery. Science 249: 1527–1533, 1990PubMedCrossRefGoogle Scholar
  63. Larrick JW. Native interleukin 1 inhibitors. Immunology Today 10: 61–66, 1989PubMedCrossRefGoogle Scholar
  64. Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. Journal of Clinical Oncology 7: 7–20, 1989PubMedGoogle Scholar
  65. Lefkowitz EJ, Fleischmann Jr WR. An inhibitor of interferon action: 1. Physical association of the inhibitor with interferon-gamma. Journal of Interferon Research 5: 85–99, 1985PubMedCrossRefGoogle Scholar
  66. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, et al. In vivo administration of purified human interleukin 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. Journal of Immunology 135: 2865–2875, 1985Google Scholar
  67. Lotze MT, Robb RJ, Sharrow SO, Frana LW, Rosenberg SA. Systemic administration of interleukin-2 in humans. Journal of Biological Response Modifiers 3: 475–482, 1984PubMedGoogle Scholar
  68. Marmenout A, Fransen L, Tavernier J, Van Der Heyden J, Tizard R, et al. Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. European Journal of Biochemistry 152: 515–522, 1985PubMedCrossRefGoogle Scholar
  69. Matsuda T, Hirano T, Nagasawa S, Kishimoto T. Identification of α2-macroglobulin as a carrier protein for IL-6. Journal of Immunology 142: 148–152, 1989Google Scholar
  70. Metcalf D. The consequences of excess levels of haemopoietic growth factors. British Journal of Haematology 75: 1–3, 1990PubMedCrossRefGoogle Scholar
  71. Metcalf D, Nicola NA. Tissue localization and fate in mice of injected multipotential colony-stimulating factor. Proceedings of the National Academy of Sciences of the United States of America 85: 3160–3164, 1988PubMedCrossRefGoogle Scholar
  72. Milici AJ, Watrous NE, Stukenbrok H, Palade GE. Transcytosis of albumin in capillary endothelium. Journal of Cellular Biology 105: 2603–2612, 1987CrossRefGoogle Scholar
  73. Moritz T, Niederle N, Baumann J, May D, Kurschel E, et al. Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease. Cancer Immunology and Immunotherapy 29: 144–150, 1989PubMedGoogle Scholar
  74. Mulé JJ, McIntosh JK, Jablons DM, Rosenberg SA. Antitumor activity of recombinant interleukin 6 in mice. Journal of Experimental Medicine 171: 629–636, 1990PubMedCrossRefGoogle Scholar
  75. Mühlradt PF, Opitz HG. Clearance of interleukin 2 from the blood of normal and T cell-depleted mice. European Journal of Immunology 12: 983–985, 1982PubMedCrossRefGoogle Scholar
  76. Newton RC, Uhl J, Covington M, Back O. The distribution and clearance of radiolabeled human interleukin-1 beta in mice. Lymphokine Research 7: 207–216, 1988PubMedGoogle Scholar
  77. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. Journal of Experimental Medicine 170: 1409–1414, 1989PubMedCrossRefGoogle Scholar
  78. Ohnishi H, Lin KM, Ming Chu T. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Cancer Research 50: 1107–1112, 1990PubMedGoogle Scholar
  79. Pacini A, Maioli E, Bocci V, Pessina GP. Studies on tumor necrosis factor (TNF): III. Plasma disappearance curves after intramuscular, subcutaneous, intraperitoneal and oral administration of human recombinant TNF. Cancer Drug Delivery 4: 17–23, 1987PubMedCrossRefGoogle Scholar
  80. Papa MZ, Vetto JT, Ettinghausen SE, Mulé JJ, Rosenberg SA. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Research 46: 5618–5623, 1986PubMedGoogle Scholar
  81. Pessina GP, Pacini A, Bocci V, Maioli E, Naldini A. Studies on tumor necrosis factor (TNF): II Metabolic fate and distribution of human recombinant TNF. Lymphokine Research 6: 35–43, 1987PubMedGoogle Scholar
  82. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, et al. Biological activity of recombinant human interleukin-2 produced in escherichia coli. Science 223: 1412–1415, 1984PubMedCrossRefGoogle Scholar
  83. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 alone. New England Journal of Medicine 316: 889–897, 1987PubMedCrossRefGoogle Scholar
  84. Sanders LM. Drug delivery systems and routes of administration of peptide and protein drugs. European Journal of Drug Metabolism and Pharmacokinetics 15: 95–102, 1990PubMedCrossRefGoogle Scholar
  85. Sarna G, Collins J, Figlin R, Robertson P, Altrock B, et al. A pilot study of intralymphatic interleukin-2: II. Clinical and biological effects. Journal of Biological Response Modifiers 9: 81–86, 1990PubMedGoogle Scholar
  86. Seckinger P, Zhang JH, Haputmann B, Dayer JM. Characterization of a tumor necrosis factor α (TNF-α) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proceedings of the National Academy of Sciences of the United States of America 87: 5188–5192, 1990PubMedCrossRefGoogle Scholar
  87. Shau H, Isacescu V, Ibayashi Y, Tokuda Y, Golub SH, et al. A pilot study of intralymphatic interleukin-2: 1. Cytotoxic and surface marker changes of peripheral blood lykmphocytes. Journal of Biological Response Modifiers 9: 71–80, 1990PubMedGoogle Scholar
  88. Shibata M. Hypothalamic neuronal responses to cytokines. Yale Journal of Biology and Medicine 63: 147–156, 1990PubMedGoogle Scholar
  89. Siegel JP, Lane HC, Stocks NI, Quinnan Jr GV, Fauci AS. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome. Journal of Biological Response Modifiers 4: 596–601, 1985PubMedGoogle Scholar
  90. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: a phase I and pharmacologic study. Journal of the National Cancer Institute 80: 1039–1044, 1988PubMedCrossRefGoogle Scholar
  91. Stephens KE, Ishizaka A, Larrick JW, Raffin TA. Tumor necrosis factor causes increased pulmonary permeability and edema. American Review of Respiratory Disease 137: 1364–1370, 1988PubMedGoogle Scholar
  92. Stitt JT. Passage of immunomodulators across the blood-brain barrier. Yale Journal of Biology and Medicine 63: 121–131, 1990PubMedGoogle Scholar
  93. Townsend Y, Cranston WI. Sites of clearance of leucocyte pyrogen in the rabbit. Clinical Science 56: 265–268, 1979PubMedGoogle Scholar
  94. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662–664, 1987PubMedCrossRefGoogle Scholar
  95. Waage A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clinical Immunology and Immunopathology 45: 348–355, 1987PubMedCrossRefGoogle Scholar
  96. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New England Journal of Medicine 316: 898–905, 1987PubMedCrossRefGoogle Scholar
  97. Whitehead RP, Ward D, Hemingway L, Hemstreet III GP, Bradley E, et al. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Research 50: 6708–6715, 1990PubMedGoogle Scholar
  98. Zimmerman RJ, Aukerman SL, Katre NV, Winkelhake JL, Young JD. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models. Cancer Research 49: 6521–6528, 1989PubMedGoogle Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Velio Bocci
    • 1
  1. 1.Institute of General Physiology and Nutritional Sciences, Faculty of PharmacyUniversity of SienaSienaItaly

Personalised recommendations